Triple

T11074322
Position Surface form Disambiguated ID Type / Status
Subject ERBB2 E261825 entity
Predicate therapeuticTargetOf P37016 FINISHED
Object trastuzumab E46088 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: trastuzumab | Statement: [ERBB2, therapeuticTargetOf, trastuzumab]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: trastuzumab
Context triple: [ERBB2, therapeuticTargetOf, trastuzumab]
  • A. Herceptin chosen
    Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
  • B. pertuzumab
    Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
  • C. lapatinib
    Lapatinib is an oral small-molecule tyrosine kinase inhibitor used primarily to treat HER2-positive breast cancer.
  • D. Ibrance
    Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
  • E. fam-trastuzumab deruxtecan
    Fam-trastuzumab deruxtecan is an antibody–drug conjugate used primarily to treat HER2-positive cancers by delivering a cytotoxic payload directly to HER2-expressing tumor cells.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: therapeuticTargetOf
Context triple: [ERBB2, therapeuticTargetOf, trastuzumab]
  • A. hasMolecularTarget chosen
    Indicates that one entity (such as a drug or compound) is directed toward, binds to, or specifically interacts with a particular molecular target (such as a protein, receptor, or gene).
  • B. hasTargetDisease
    Indicates that an entity (such as a treatment, study, or intervention) is directed toward, intended to affect, or primarily concerned with a specified disease.
  • C. regulatoryTarget
    Indicates that one entity is subject to control, influence, or governance by another entity under a regulatory or rule-based framework.
  • D. targetsDiseaseVector
    Indicates that an entity is directed at, designed to affect, or intended to control a particular disease-carrying vector organism.
  • E. knownForTreatmentOf
    Indicates that an entity is recognized or notable for providing treatment or medical care for a particular condition, disease, or type of patient.
  • F. None of above.

Provenance (4 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d6aa9983c08190b0ef61603b69feac completed April 8, 2026, 7:20 p.m.
NER Named-entity recognition batch_69d7994e32fc8190a6591d9e82b68f75 completed April 9, 2026, 12:19 p.m.
NED1 Entity disambiguation (via context triple) batch_69e3e76a49fc8190945f4770bf808b43 completed April 18, 2026, 8:19 p.m.
PD Predicate disambiguation batch_69d74415403c81909778bcd829e8832e completed April 9, 2026, 6:15 a.m.
Created at: April 8, 2026, 9:26 p.m.